Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UPenn Engages CRO To Monitor AE Reporting For Gene Therapy Trials

Executive Summary

The University of Pennsylvania's gene therapy institute has engaged a contract research organization to monitor adverse event reporting and other administrative and regulatory requirements for its gene therapy trials.

You may also be interested in...



CROs May Offer More Objective Monitoring For Gene Therapy - FDA's Noguchi

Gene therapy clinical trial sponsors may want to consider employing contract research organizations to help achieve more objective and independent monitoring of trial conduct, FDA Cellular and Gene Therapies Division Director Phillip Noguchi, MD, suggested at the Drug Information Association annual meeting June 15 in San Diego.

CROs May Offer More Objective Monitoring For Gene Therapy - FDA's Noguchi

Gene therapy clinical trial sponsors may want to consider employing contract research organizations to help achieve more objective and independent monitoring of trial conduct, FDA Cellular and Gene Therapies Division Director Phillip Noguchi, MD, suggested at the Drug Information Association annual meeting June 15 in San Diego.

TKT Hemophilia Gene Therapy Trial Halted Despite No Evidence Of Problems

The suspension of Transkaryotic Therapies' gene therapy trial at Beth Israel Deaconess Medical Center could signal the beginning of a trend of gene therapy trial suspensions as a cautionary measure even if the study shows no sign of problems.

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel